Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 325

1.

Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology.

Wilkins A, Melcher A, Somaiah N.

Clin Oncol (R Coll Radiol). 2018 Jul 21. pii: S0936-6555(18)30312-1. doi: 10.1016/j.clon.2018.07.001. [Epub ahead of print] No abstract available.

PMID:
30041845
2.

Oncolytic Virotherapy: Single Cycle Cures or Repeat Treatments? (Repeat Dosing Is Crucial!).

Melcher A.

Mol Ther. 2018 Aug 1;26(8):1875-1876. doi: 10.1016/j.ymthe.2018.07.002. Epub 2018 Jul 14. No abstract available.

PMID:
30017879
3.

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.

Annels NE, Arif M, Simpson GR, Denyer M, Moller-Levet C, Mansfield D, Butler R, Shafren D, Au G, Knowles M, Harrington K, Vile R, Melcher A, Pandha H.

Mol Ther Oncolytics. 2018 Feb 14;9:1-12. doi: 10.1016/j.omto.2018.02.001. eCollection 2018 Jun 29.

4.

Synergistic antitumour effects of rapamycin and oncolytic reovirus.

Comins C, Simpson GR, Rogers W, Relph K, Harrington K, Melcher A, Roulstone V, Kyula J, Pandha H.

Cancer Gene Ther. 2018 May 3. doi: 10.1038/s41417-018-0011-8. [Epub ahead of print]

PMID:
29720674
5.

Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.

Yip K, Melcher A, Harrington K, Illidge T, Nobes J, Webster A, Smith D, Lorigan P, Nathan P, Larkin J.

Clin Oncol (R Coll Radiol). 2018 Apr;30(4):201-203. doi: 10.1016/j.clon.2018.01.001. No abstract available.

PMID:
29402599
6.

Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.

Taggart D, Andreou T, Scott KJ, Williams J, Rippaus N, Brownlie RJ, Ilett EJ, Salmond RJ, Melcher A, Lorger M.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1540-E1549. doi: 10.1073/pnas.1714089115. Epub 2018 Jan 31.

7.

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Khan AA, Paget JT, McLaughlin M, Kyula JN, Wilkinson MJ, Pencavel T, Mansfield D, Roulstone V, Seth R, Halle M, Somaiah N, Boult JKR, Robinson SP, Pandha HS, Vile RG, Melcher AA, Harris PA, Harrington KJ.

Sci Transl Med. 2018 Jan 24;10(425). pii: eaar2041. doi: 10.1126/scitranslmed.aar2041.

8.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

9.

Developing reference criteria for the ecological status of West African rivers.

Kaboré I, Moog O, Ouéda A, Sendzimir J, Ouédraogo R, Guenda W, Melcher AH.

Environ Monit Assess. 2017 Dec 2;190(1):2. doi: 10.1007/s10661-017-6360-1.

10.

High-frequency measurements reveal spatial and temporal patterns of dissolved organic matter in an urban water conveyance.

Mihalevich BA, Horsburgh JS, Melcher AA.

Environ Monit Assess. 2017 Oct 30;189(11):593. doi: 10.1007/s10661-017-6310-y.

PMID:
29086038
11.

Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.

Kottke T, Evgin L, Shim KG, Rommelfanger D, Boisgerault N, Zaidi S, Diaz RM, Thompson J, Ilett E, Coffey M, Selby P, Pandha H, Harrington K, Melcher A, Vile R.

Cancer Immunol Res. 2017 Nov;5(11):1029-1045. doi: 10.1158/2326-6066.CIR-17-0175. Epub 2017 Oct 15.

12.

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion.

Cockle JV, Brüning-Richardson A, Scott KJ, Thompson J, Kottke T, Morrison E, Ismail A, Carcaboso AM, Rose A, Selby P, Conner J, Picton S, Short S, Vile R, Melcher A, Ilett E.

Mol Ther Oncolytics. 2017 May 2;5:75-86. doi: 10.1016/j.omto.2017.04.002. eCollection 2017 Jun 16.

13.

An urban observatory for quantifying phosphorus and suspended solid loads in combined natural and stormwater conveyances.

Melcher AA, Horsburgh JS.

Environ Monit Assess. 2017 Jun;189(6):285. doi: 10.1007/s10661-017-5974-7. Epub 2017 May 23.

PMID:
28536909
14.

Immunogenicity of self tumor associated proteins is enhanced through protein truncation.

Kottke T, Shim KG, Alonso-Camino V, Zaidi S, Maria Diaz R, Pulido J, Thompson J, Rajani KR, Evgin L, Ilett E, Pandha H, Harrington K, Selby P, Melcher A, Vile R.

Mol Ther Oncolytics. 2016 Dec 7;3:16030. eCollection 2016.

15.

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.

Samson A, Bentham MJ, Scott K, Nuovo G, Bloy A, Appleton E, Adair RA, Dave R, Peckham-Cooper A, Toogood G, Nagamori S, Coffey M, Vile R, Harrington K, Selby P, Errington-Mais F, Melcher A, Griffin S.

Gut. 2018 Mar;67(3):562-573. doi: 10.1136/gutjnl-2016-312009. Epub 2016 Nov 15.

16.

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.

Ilett E, Kottke T, Thompson J, Rajani K, Zaidi S, Evgin L, Coffey M, Ralph C, Diaz R, Pandha H, Harrington K, Selby P, Bram R, Melcher A, Vile R.

Gene Ther. 2017 Jan;24(1):21-30. doi: 10.1038/gt.2016.70. Epub 2016 Oct 25.

17.

A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.

Holyoake DL, Ward E, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Patel N, Silva M, Mukherjee S, Strauss VY, Odondi L, Fokas E, Melcher A, Hawkins MA.

BMC Cancer. 2016 Sep 13;16(1):728. doi: 10.1186/s12885-016-2765-4.

18.

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances.

Simpson GR, Relph K, Harrington K, Melcher A, Pandha H.

Oncolytic Virother. 2016 Jan 6;5:1-13. doi: 10.2147/OV.S66083. eCollection 2016. Review.

19.

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.

Mansfield DC, Kyula JN, Rosenfelder N, Chao-Chu J, Kramer-Marek G, Khan AA, Roulstone V, McLaughlin M, Melcher AA, Vile RG, Pandha HS, Khoo V, Harrington KJ.

Gene Ther. 2016 Apr;23(4):357-68. doi: 10.1038/gt.2016.5. Epub 2016 Jan 27.

20.

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

Turnbull S, West EJ, Scott KJ, Appleton E, Melcher A, Ralph C.

Viruses. 2015 Dec 2;7(12):6291-312. doi: 10.3390/v7122938. Review.

21.

Talimogene laherparepvec in the treatment of melanoma.

Appleton ES, Turnbull S, Ralph C, West E, Scott K, Harrington K, Pandha H, Melcher A.

Expert Opin Biol Ther. 2015;15(10):1517-30. Review.

PMID:
26629575
22.

Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.

Blanchard M, Shim KG, Grams MP, Rajani K, Diaz RM, Furutani KM, Thompson J, Olivier KR, Park SS, Markovic SN, Pandha H, Melcher A, Harrington K, Zaidi S, Vile R.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):577-87. doi: 10.1016/j.ijrobp.2015.07.2274. Epub 2015 Jul 26.

23.

Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

Cockle JV, Rajani K, Zaidi S, Kottke T, Thompson J, Diaz RM, Shim K, Peterson T, Parney IF, Short S, Selby P, Ilett E, Melcher A, Vile R.

Neuro Oncol. 2016 Apr;18(4):518-27. doi: 10.1093/neuonc/nov173. Epub 2015 Sep 26.

24.

Anti-cancer effects of oncolytic viral therapy combined with photodynamic therapy in human pancreatic cancer cell lines.

Khaled YS, Wright K, Melcher A, Jayne D.

Lancet. 2015 Feb 26;385 Suppl 1:S56. doi: 10.1016/S0140-6736(15)60371-3.

PMID:
26312878
25.

Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, Shim KG, Diaz RM, Pandha H, Harrington K, Coffey M, Melcher A, Vile R.

Mol Ther. 2016 Feb;24(1):166-74. doi: 10.1038/mt.2015.156. Epub 2015 Aug 27.

26.

A new fish-based multi-metric assessment index for cyprinid streams in the Iranian Caspian Sea Basin.

Mostafavi H, Schinegger R, Melcher A, Moder K, Mielach C, Schmutz S.

Limnologica. 2015 Mar;51:37-52.

27.

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.

Parrish C, Scott GB, Migneco G, Scott KJ, Steele LP, Ilett E, West EJ, Hall K, Selby PJ, Buchanan D, Varghese A, Cragg MS, Coffey M, Hillmen P, Melcher AA, Errington-Mais F.

Leukemia. 2015 Sep;29(9):1799-810. doi: 10.1038/leu.2015.88. Epub 2015 Mar 27.

28.

Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.

Jebar AH, Errington-Mais F, Vile RG, Selby PJ, Melcher AA, Griffin S.

J Gen Virol. 2015 Jul;96(Pt 7):1533-50. doi: 10.1099/vir.0.000098. Epub 2015 Feb 23. Review.

29.

Cell migration in paediatric glioma; characterisation and potential therapeutic targeting.

Cockle JV, Picton S, Levesley J, Ilett E, Carcaboso AM, Short S, Steel LP, Melcher A, Lawler SE, Brüning-Richardson A.

Br J Cancer. 2015 Feb 17;112(4):693-703. doi: 10.1038/bjc.2015.16. Epub 2015 Jan 27.

30.

Adenovirally delivered enzyme prodrug therapy with herpes simplex virus-thymidine kinase in composite tissue free flaps shows therapeutic efficacy in rat models of glioma.

Seth R, Khan AA, Pencavel TD, Wilkinson MJ, Kyula JN, Simpson G, Pandha H, Melcher A, Vile R, Harris PA, Harrington KJ.

Plast Reconstr Surg. 2015 Feb;135(2):475-87. doi: 10.1097/PRS.0000000000000878.

31.

BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.

Roulstone V, Pedersen M, Kyula J, Mansfield D, Khan AA, McEntee G, Wilkinson M, Karapanagiotou E, Coffey M, Marais R, Jebar A, Errington-Mais F, Melcher A, Vile R, Pandha H, McLaughlin M, Harrington KJ.

Mol Ther. 2015 May;23(5):931-942. doi: 10.1038/mt.2015.15. Epub 2015 Jan 26.

32.

Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.

Zaidi S, Blanchard M, Shim K, Ilett E, Rajani K, Parrish C, Boisgerault N, Kottke T, Thompson J, Celis E, Pulido J, Selby P, Pandha H, Melcher A, Harrington K, Vile R.

Mol Ther. 2015 May;23(5):845-856. doi: 10.1038/mt.2014.253. Epub 2014 Dec 29.

33.

Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.

El-Sherbiny YM, Holmes TD, Wetherill LF, Black EV, Wilson EB, Phillips SL, Scott GB, Adair RA, Dave R, Scott KJ, Morgan RS, Coffey M, Toogood GJ, Melcher AA, Cook GP.

Clin Exp Immunol. 2015 Apr;180(1):98-107. doi: 10.1111/cei.12562.

34.

Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.

Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM, Melcher AA, Vile R, Harrington KJ, de Bono J, Spicer J.

Clin Cancer Res. 2015 Mar 15;21(6):1305-12. doi: 10.1158/1078-0432.CCR-14-1770. Epub 2014 Nov 25.

35.

The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.

Alonso-Camino V, Rajani K, Kottke T, Rommelfanger-Konkol D, Zaidi S, Thompson J, Pulido J, Ilett E, Donnelly O, Selby P, Pandha H, Melcher A, Harrington K, Diaz RM, Vile R.

Mol Ther. 2014 Nov;22(11):1936-48. doi: 10.1038/mt.2014.134. Epub 2014 Jul 25.

36.

Future clinical potential of oncolytic virotherapy for pediatric CNS tumors.

Cockle JV, Picton SV, Melcher A.

CNS Oncol. 2013 Jul;2(4):307-10. doi: 10.2217/cns.13.25. No abstract available.

37.

Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.

Ilett E, Kottke T, Donnelly O, Thompson J, Willmon C, Diaz R, Zaidi S, Coffey M, Selby P, Harrington K, Pandha H, Melcher A, Vile R.

Mol Ther. 2014 Oct;22(10):1851-63. doi: 10.1038/mt.2014.118. Epub 2014 Jun 24.

38.

Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses.

Dave RV, Jebar AH, Jennings VA, Adair RA, West EJ, Errington-Mais F, Toogood GJ, Melcher AA.

Surgeon. 2014 Aug;12(4):210-20. doi: 10.1016/j.surge.2014.01.001. Epub 2014 Feb 4. Review.

PMID:
24502935
39.

Applications of coxsackievirus A21 in oncology.

Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F.

Oncolytic Virother. 2014 Apr 10;3:47-55. doi: 10.2147/OV.S56322. eCollection 2014. Review.

40.

Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.

Kottke T, Boisgerault N, Diaz RM, Donnelly O, Rommelfanger-Konkol D, Pulido J, Thompson J, Mukhopadhyay D, Kaspar R, Coffey M, Pandha H, Melcher A, Harrington K, Selby P, Vile R.

Nat Med. 2013 Dec;19(12):1625-1631. doi: 10.1038/nm.3397. Epub 2013 Nov 17.

41.

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.

Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, Harrington K, Young A, Hall GD, Coffey M, Selby P, Errington-Mais F, Melcher AA.

Int J Cancer. 2014 Mar 1;134(5):1091-101. doi: 10.1002/ijc.28450. Epub 2013 Sep 18.

42.

Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells.

Tai LH, Zhang J, Scott KJ, de Souza CT, Alkayyal AA, Ananth AA, Sahi S, Adair RA, Mahmoud AB, Sad S, Bell JC, Makrigiannis AP, Melcher AA, Auer RC.

Clin Cancer Res. 2013 Sep 15;19(18):5104-15. doi: 10.1158/1078-0432.CCR-13-0246. Epub 2013 Jul 23.

43.

Live viruses to treat cancer.

Donnelly O, Harrington K, Melcher A, Pandha H.

J R Soc Med. 2013 Aug;106(8):310-4. doi: 10.1177/0141076813494196. Epub 2013 Jul 3. Review.

44.

Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.

Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, Embry A, Saenz D, Poeschla E, Pandha H, Harrington K, Melcher A, Selby P, Vile R.

Mol Ther. 2013 Aug;21(8):1507-16. doi: 10.1038/mt.2013.116. Epub 2013 Jun 11.

45.

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.

Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, Chen NG, Yu YA, Zhang Q, Melcher AA, Vile RG, Pandha HS, Ajaz M, Szalay AA, Harrington KJ.

Oncogene. 2014 Mar 27;33(13):1700-12. doi: 10.1038/onc.2013.112. Epub 2013 Apr 29.

46.

Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.

Kyula JN, Roulstone V, Karapanagiotou EM, Melcher AA, Harrington KJ.

Expert Opin Biol Ther. 2012 Dec;12(12):1669-78. doi: 10.1517/14712598.2012.745507. Review. Erratum in: Expert Opin Biol Ther. 2013 Jan;13(1):147.

PMID:
23140488
47.

Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.

Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington KJ, Toogood G, Melcher AA.

Int J Cancer. 2013 May 15;132(10):2327-38. doi: 10.1002/ijc.27918. Epub 2012 Nov 26.

48.

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG.

Mol Ther. 2013 Feb;21(2):348-57. doi: 10.1038/mt.2012.204. Epub 2012 Sep 25. Erratum in: Mol Ther. 2013 Apr;21(4):913. Grau, Marta C [corrected to Compte, Marta].

49.

The hitchhiker's guide to virotherapy.

Donnelly O, Vile R, Pandha H, Harrington K, Melcher A.

Oncotarget. 2012 Aug;3(8):735-6. No abstract available.

50.

What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?

Donnelly OG, Melcher AA, Vile RG, Pulido J.

Immunotherapy. 2012 Aug;4(8):749-51. doi: 10.2217/imt.12.65. No abstract available.

Supplemental Content

Loading ...
Support Center